SummaryA sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population.See related article by Nagler et al., p. 4258

中文翻译：

---

复发/难治性 AML 中的无关同种异体干细胞移植：拓宽黄砖路

摘要相当一部分急性髓系白血病 (AML) 患者未能获得缓解。造血干细胞移植（HSCT）是唯一具有长期生存潜力的干预措施。最近的急性白血病工作组 (ALWP)/欧洲血液和骨髓移植协会 (EBMT) 分析报告显示，接受移植的活动性疾病患者的移植后生存率显着提高。减少复发是生存的最大贡献者，这也是这个充满挑战的人群中乐观的一个原因。参见 Nagler 等人的相关文章，第 17 页。4258